Lakefront biotherapeutics

Progress with Purpose

Half-Year Financial Report 2026

About This Report

This report contains information required under Belgian law. Lakefront Biotherapeutics NV is a limited liability company organized under the laws of Belgium, having its registered office at Schaliënhoevedreef 20T, 2800 Mechelen, Belgium and registered with the Crossroads Enterprise Database (RPR Antwerp – division Mechelen) under number 0466.460.429.

Throughout this report, the term “Lakefront Biotherapeutics NV” refers solely to the non-consolidated Belgian company, and references to “we,” “our,” “the group” or “Lakefront” include Lakefront Biotherapeutics NV together with its subsidiaries.

This report is published in Dutch and in English. Lakefront will use reasonable efforts to ensure the translation and conformity between the Dutch and English versions. In case of inconsistency between the Dutch and the English version, the Dutch version shall prevail.

This report is available free of charge and upon request addressed to:

Lakefront Biotherapeutics NV
Investor Relations
Schaliënhoevedreef 20T
2800 Mechelen, Belgium

Tel: +32 15 34 29 00
Email: **ir@lakefrontbio.com**

A digital version of this report is available on our website, **www.lakefrontbio.com**.

We will use reasonable efforts to ensure the accuracy of the digital version, but we do not assume responsibility if inaccuracies or inconsistencies with the printed or PDF document arise as a result of any electronic transmission. Other information on our website or on other websites does not form a part of this report.

With the exception of filgotinib’s approval as Jyseleca® (which was transferred to Alfasigma in early 2024) for the treatment of moderate-to-severe rheumatoid arthritis and ulcerative colitis by the European Commission, Great Britain’s Medicines and Healthcare products Regulatory Agency, and the Japanese Ministry of Health, Labour and Welfare, our drug candidates mentioned in this report are investigational; their efficacy and safety have not been fully evaluated by any regulatory authority.

Table of Contents



Management Report

Management Report

Letter from our CEO

Dear Shareholders,

The first half of 2026 marked the beginning of a new chapter for our company.

We became Lakefront Biotherapeutics, a name that reflects both the strategic direction we have set and the company we are building. It aligns our identity with our focus: advancing programs that have the potential to deliver meaningful outcomes for patients improved quality of life, while creating sustainable long-term value for shareholders. While our name has changed, our conviction has not.

The defining milestone of the first half of 2026 was the completion of the acquisition of Ouro Medicines with Gilead Sciences. This transaction represents a significant step forward in the execution of our strategy.

It brings gamgertamig into our portfolio, a clinical-stage T-cell engager with the potential to be first-in-class and best-in-class in serious antibody-mediated autoimmune diseases. We believe this program has the potential to address significant unmet medical needs and, if successfully developed and approved, to represent a meaningful long-term value creation opportunity for our shareholders. We've also in-licensed a preclinical portfolio of three additional autoimmune and inflammatory programs originally from Ouro, which further expands our pipeline and future opportunity. While early, we're very excited about the potential for these assets.

Henry Gosebruch, Chief Executive Officer

The significance of the Ouro transaction extends beyond the acquisition itself. It advances our strategy in three important ways:

- First, it strengthens our portfolio with a clinical-stage program that we believe has a compelling profile and an attractive path forward in serious autoimmune diseases.

- Second, it expands our organization with an accomplished development team, that brings deep experience in advancing innovative medicines. At Lakefront, we had already assembled a team with strong business development expertise and a shared mission to deploy capital in a disciplined and selective way. With the addition of Ouro's team and assets, we have further strengthened our ability to execute our strategy.

- Third, the transaction enhances our financial and strategic flexibility. As part of the transaction, we amended our legacy Option, License and Collaboration Agreement (OLCA) with Gilead, enabling us to designate an additional $500 million of our cash for R&D or strategic transactions outside of Gilead partnerships, including up to $150 million for potential returns of capital. Shortly after closing, we announced an initial €50 million share repurchase program, reflecting our continued commitment to disciplined capital allocation and shareholder value creation.

The transaction also underscores the strength of our strategic relationship with Gilead. We believe this relationship can be a competitive advantage for us, particularly if we continue to evaluate opportunities that could be synergistic with Gilead's portfolio and capabilities. Together, we have structured a collaboration that allows Lakefront to participate meaningfully in the development of gamgertamig and the preclinical assets, while enabling our shareholders to benefit from the potential value creation as these programs advance.

Looking ahead, our priorities are clear.

With the closure of the acquisition of Ouro Medicines with Gilead, we are combining the strengths of our teams to expand the already rapid development of our lead asset, gamgertamig, along with progressing the preclinical portfolio; completing the wind-down of our cell therapy activities in a responsible and disciplined manner; executing our initial share repurchase program; and continuing to evaluate additional business development opportunities with financial discipline and thorough strategic assessment.

Lakefront is a focused and well-capitalized biotechnology company. We combine clinical development capabilities, business development expertise and financial flexibility to pursue opportunities that we believe can deliver meaningful patient impact and attractive long-term returns. We forecast having at least €1.6 billion of capital remaining to fund additional strategic transactions and other capital allocation priorities after funding the portfolio to first gamgertamig approval.

We appreciate the continued support of our employees, patients, partners and shareholders as we build the next phase of our company.

Sincerely,

Henry Gosebruch
Chief Executive Officer
Lakefront Biotherapeutics

A conversation with Henry and Gino

We sat down with our CEO, Henry Gosebruch, and Board Chair, Gino Santini, to discuss the company's first six months of 2026, the strategic significance of the Ouro transaction, the evolution of Lakefront's pipeline and the priorities for the remainder of the year.

Henry, in April 2026, Gino Santini was elected to the Board of Directors and appointed Board Chair. Can you help us understand why his background was the right fit?

Gino is a seasoned pharmaceutical executive who spent 27 years in various roles at Eli Lilly, including as President of US Operations and as Senior Vice President of Corporate Strategy and Business Development. Following his retirement from Lilly, he's been a sought-after board member and has helped guide a number of biotechnology companies through transformations and value creation events.

I have known Gino for nearly two decades and am confident that his extensive operational, strategic, and business development expertise, shaped by decades of global leadership in our sector, will be invaluable as we execute our strategy to deliver meaningful patient impact and sustainable shareholder returns.

More broadly, I am really pleased with the talented group of directors who joined us to serve on our Board. As we transform, it's important that the Board brings the right mix of capabilities and background. Our Board brings the skills and experience that are needed to provide effective oversight and strategic guidance to the company.

Gino, what is the Board focused on going forward?

The Board's priority has been to define a clear and sustainable path forward for the company. We will focus on guiding management on building the capabilities needed to advance the new portfolio of exciting programs we acquired in connection with the Ouro transaction and to oversee the plan on maximizing the opportunities to create value with these programs.

Going forward, Lakefront has a very high bar to deploy cash for business development. We will continue to focus on clinically derisked opportunities in the areas where we believe we could bring unique insights that represent competitive advantage.

Henry, how would you summarize the first six months of 2026?

The first half of 2026 was about moving from strategic review to execution. Our objective wasn't incremental rebuilding, but a fundamental reshaping of the company around programs we believe are capable of delivering meaningful patient impact and sustainable shareholder returns.

We began the year with a clear focus: to reshape the company around opportunities where we believe we can have the greatest patient impact and create shareholder value.

That meant taking decisive actions. We initiated the wind-down of our cell therapy operations. We became Lakefront Biotherapeutics. With Gilead, we completed the acquisition of Ouro Medicines, which gives us an exciting portfolio to advance. We also strengthened our leadership and governance, and we launched an initial €50 million stock repurchase program.

Gino, how do you view the strategic relationship with Gilead Sciences?

I believe the Gilead relationship can be a strategic advantage for Lakefront.

This advantage is exemplified in the structure of the Ouro Medicines transaction, which allows each company to contribute where it is best positioned. Lakefront is responsible for ongoing and future Phase 1/2 clinical studies of gamgertamig. Gilead will lead registrational and later-stage studies and is responsible for commercialization outside of Keymed's territories. The two parties split the deal costs 50/50, enabling Lakefront to deploy only a portion of our available cash and leaving the majority of our capital available for other transactions, reflecting our clear focus on prudent capital allocation.

For Lakefront, that means we can play a meaningful role in advancing the program while retaining the potential to participate in long-term value through tiered royalties. In addition, the transaction includes a preclinical portfolio of three autoimmune programs, where Gilead holds an option to participate following clinical proof-of-concept through a 50/50 profit share, further extending the long-term value opportunity.

Henry, how should investors think about the immunology pipeline after the Ouro transaction?

The Ouro transaction is a significant milestone because it gives us a promising clinical-stage asset, expands our development opportunities in immunology, and strengthens our ability to create long-term value.

Accelerating the development of gamgertamig is front and center for us. The program has already received both Fast Track and Orphan Drug Designation from the U.S. FDA for autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP), and we believe it has the potential to enter registrational studies in 2027.

Importantly, we're continuing to build momentum across the clinical program. We currently have two Phase 1b studies actively enrolling patients across a range of autoimmune diseases. One study is evaluating gamgertamig in autoimmune cytopenias, including ITP and AIHA, while a second study is focused on seropositive autoimmune diseases such as idiopathic inflammatory myositis, Sjögren's disease, pemphigus vulgaris, and pemphigus foliaceus. These studies are underway across multiple countries, including the United States, Australia, New Zealand, Czech Republic, and Japan.

Looking ahead, we expect to continue expanding the clinical development program, including the initiation of proof-of-concept basket studies in additional autoimmune diseases in 2027.

In addition, the transaction brought several earlier-stage autoimmune and inflammatory disease programs that provide future opportunities and further reinforce our long-term focus on targeted immune modulation.

Henry, what recent leadership and governance changes supported this next phase?

As we previously mentioned, Gino became Chair of the Board following shareholder approval at the company's Annual General Meeting. We also added Dr. Paulo Fontoura to our Board earlier this year, although recently, Paulo tendered his resignation from the Board following his announced appointment as Global Head of R&D at Sanofi. We look forward to identifying a suitable replacement for Paulo soon.

I am extremely pleased with the management talent we have been able to attract. Operationally, the appointment of Dr. Eric Hedrick as Chief Medical Officer is especially important. Eric brings a twenty-five year track record successfully developing effective and commercially successful therapies to this important role.

We also strengthened the organization with Tania Philipp appointed as Chief People Officer. Tania's established background supporting the vision, mission and objectives of life sciences companies is essential as we continue to execute on our transformation, welcome new colleagues and build the Lakefront culture.

We also are delighted that we have added an impressive team of individuals from Ouro to Lakefront, including Ruth Lan, Vice President Research and Translation, who will also serve on our senior leadership team.

Gino, how is Lakefront thinking about capital allocation?

Lakefront's cash position is a strategic asset, and capital allocation is one of the Board's most important responsibilities. The Company ended 2025 with cash and financial investments of approximately €3 billion. Following the Ouro transaction and after funding the portfolio to first approval for gamgertamig, we forecast to have at least €1.6 billion in cash remaining to fund other strategic opportunities. Lakefront benefits from the financial discipline and strong balance sheet built over many years. Our task now is to deploy that capital in a way that supports long-term value creation.

The Ouro transaction is a good example. It was a significant investment, but one we believe is consistent with the Company's strategy and our objectives of adding proof-of-concept stage programs. At the same time, the transaction created additional flexibility through the amendment to the legacy Gilead collaboration.

Another example is the €50 million share repurchase program recently announced by Lakefront. The authorization for the Board to acquire Lakefront's own shares was approved by the shareholders at the Extraordinary General Meeting in April 2026. The objective of the program is to deliver shareholder value. Following the closing of the Ouro transaction and related impact to cash, the Company expects its year end 2026 cash and financial investments balance to be in the range of €1.975 billion to €2.050 billion. This guidance includes the announced €50M share buyback program, which was not considered in the previous guidance range.

Henry, what are the top priorities for the second half of 2026?

We have four priorities for the remainder of the year.

First, we have completed the acquisition of Ouro Medicines with Gilead and integrated the Ouro employees and operational assets. Second, we intend to accelerate the advancement of gamgertamig and the preclinical pipeline, with a focus on high-quality clinical execution. Our objective is to initiate pivotal studies for gamgertamig in 2027 and to assess the most promising indication expansion opportunities. Third, we will continue the wind-down of our cell therapy activities in a responsible and disciplined manner. And finally, we will continue to evaluate new business development opportunities using a disciplined and selective approach.

How should shareholders think about Lakefront's outlook?

Gino: Shareholders should view 2026 as a year of transition and execution. The company has changed its name, sharpened its strategy, added a new clinical development foundation through the Ouro transaction, strengthened its leadership and governance, and taken steps to return capital to shareholders.

There is still important work ahead, but we believe Lakefront is well-positioned. It is focused, well-capitalized and built around a strategy that combines savvy clinical development, business development, and disciplined capital allocation.

Henry: I agree. I'm proud of our achievements to date and optimistic about the future. We believe gamgertamig could represent a very important new type of treatment approach for immune reset therapy for patients across a large number of conditions. It has shown compelling clinical data thus far and it may have both a first-in-class advantage and best-in-class potential. I'm excited for the opportunity to accelerate its clinical development and make a difference for patients.

Lakefront symbolizes the attractive opportunity in front of us and the new beginning we have created.

Main Events in the First Six Months of 2026

Portfolio

The charts below provide an overview of our R&D pipeline in immunology comprising our product candidates that are in development as of the date of this report's publication.

Immunology

DM, dermatomyositis; SLE, systemic lupus erythematosus

We are advancing a pipeline of T-cell engagers, anchored by gamgertamig, a potential first and best-in-class BCMAxCD3 T-cell engager for autoimmune indications. Gamgertamig is being developed in collaboration with Gilead. We also in-licensed a preclinical portfolio of three additional autoimmune and inflammatory focused programs originally from Ouro with an opt-in for Gilead for a 50/50 profit split post clinical proof-of-concept for $75 million per program.



AIBD, autoimmune bullous diseases; AIC, autoimmune cytopenia; AIHA, autoimmune hemolytic anemia; APS, antiphospholipid syndrome; IIM, idiopathic inflammatory myopathy; ITP, immune thrombocytopenia; SAI, seropositive autoimmune diseases; SjD, Sjogren's disease; PF: pemphigus foliaceus; PV, pemphigus vulgaris

First Quarter 2026

See our **Q1 2026 press release**.

Second Quarter 2026 and Post-Period Update

Corporate

- Our name change to Lakefront Biotherapeutics was effective as of May 8, 2026, and the ticker on Euronext and NASDAQ (ADRs) was changed to LKFT.
- We appointed Eric Hedrick, MD, as Chief Medical Officer. This expanded leadership role supports our strategic transformation following its acquisition of Ouro Medicines' operational assets announced on June 4, 2026. Eric will report to Henry Gosebruch, CEO, and joined our Management Committee.
- We announced the initiation of a €50 million share repurchase program on June 9, 2026. Repurchases under the program may be made no later than December 31, 2026. The program was entered into with Morgan Stanley & Co International PLC. The purchased shares are held as treasury shares. As of June 30, 241,904 shares were repurchased at an average price of €25.1261.
- Paulo Fontoura resigned from the Board of Directors following Sanofi's announcement of his appointment as Global Head of R&D at Sanofi on June 22, 2026.

Immunology Portfolio

- We completed, together with Gilead Sciences (Gilead), the acquisition of Ouro Medicines (Ouro). We will collaborate on the development of gamgertamig, a potential first-in-class and best-in-class T-cell engager in autoimmune diseases.
- Gamgertamig has been granted both Fast Track and Orphan Drug Designation by the U.S. FDA for the treatment of autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP) and is expected to enter registrational studies in 2027.
- Ongoing Lakefront-sponsored clinical trials of gamgertamig in autoimmune diseases are actively enrolling, and expansion of the clinical trials program is anticipated in 2027.
  - Phase 1b study with gamgertamig in patients with autoimmune cytopenias (including ITP and AIHA) (NCT07083960), active in Australia and the United States.
  - Phase 1b study with gamgertamig in seropsoitive autoimmune diseases (including idiopathic inflammatory myositis, Sjögren's disease, pemphigus vulgaris (PV), and pemphigus foliaceus (PF)) (NCT07229144) active in Australia, New Zealand, Czech Republic, and Japan.
  - Expect to initiate proof-of-concept basket studies assessing gamgertamig in additional autoimmune diseases in 2027.
- In addition, Keymed is conducting a number of company-sponsored studies in Greater China with gamgertamig in both malignant and autoimmune indications.
- At the International Society on Thrombosis and Haemostasias (ISTH) 2026 Congress in Paris, we presented a poster on the effects of gamgertamig in a patient with active antiphospholipid antibody syndrome and concurrent autoimmune thrombocytopenia (click **here** to access the poster).

- Additionally, we in-licensed a preclinical portfolio of three autoimmune and inflammatory programs originally from Ouro with an opt-in for Gilead for a 50/50 profit split post clinical proof-of-concept for $75 million per program.
- GLPG3667 has completed the GALARISSO and GALACELA studies[1]:
  - The Phase 2 GALARISSO study in dermatomyositis (DM) has completed the 24-week open-label extension with sustained efficacy and safety consistent with previously reported results.
  - The Phase 2 GALACELA study in systemic lupus erythematosus (SLE) has completed with continued favorable safety at 48 weeks; the trial did not meet the 32-week primary endpoint and comparable 48-week secondary endpoint.
  - As part of our ongoing efforts to maximize the value of the GLPG3667 program for both patients and the Company, we are evaluating all strategic options.

1 **Galapagos Announces Topline Results from Two Phase 3-Enabling Studies with Selective TYK2 Inhibitor GLPG3667 in Dermatomyositis and Systemic Lupus Erythematosus – Lakefront Biotherapeutics**

Oncology CAR-T Cell Therapy Update

- We announced in January 2026 the start of the wind-down of our cell therapy activities. The wind-down remains on schedule and is expected to be substantially completed by the end of the third quarter of 2026.
- To support long-term patient follow-up, the HESPERIA study continues to monitor safety of all patients treated in the discontinued parent studies; associated spending is expected to remain minimal.

Financial Guidance

- Following the closing of the Ouro transaction and the related impact to cash, we expect our year end 2026 cash and financial investments balance to be in the range of €1.975 billion to €2.050 billion. This guidance includes the announced €50 million share buyback program, which was not considered in the previous guidance range.
- We forecast having at least €1.6 billion of our cash remaining for additional strategic transactions and other capital allocation priorities following funding the portfolio to first gamgertamig approval.
- All figures assume an EUR/USD exchange rate of 1.175, consistent with year-end 2025 and prior guidance. As of June 30, 2026, the EUR/USD exchange rate was 1.1394.
- These estimates are subject to change and depend on exchange rate fluctuations, and future business development activity.

Financial Highlights

Consolidated Key Figures

(thousands of €, if not stated otherwise)	**Six months ended June 30, 2026**	Six months ended June 30, 2025	Year ended December 31, 2025
Income statement			
Supply revenues	14,049	18,486	29,924
Collaboration revenues	4,542	121,779	1,082,324
Total net revenues	18,591	140,265	1,112,248
Cost of sales	(13,944)	(18,435)	(29,736)
R&D expenses	(56,486)	(278,027)	(459,421)
S&M, G&A expenses	(58,010)	(74,470)	(153,433)
Impairment of the cell therapy activities	–	–	(228,112)
Other operating income	2,635	14,932	53,493
Operating profit/loss (–)	(107,214)	(215,735)	295,039
Net financial results	123,184	(45,056)	5,832
Taxes	(140)	1,788	18,621
Net profit/loss (–) from continuing operations	15,830	(259,003)	319,492
Net profit/loss (–) from discontinued operations, net of tax	771	(148)	1,392
Net profit/loss (–)	16,601	(259,151)	320,884
Income statement from discontinued operations			
R&D expenses	220	(12,516)	(11,708)
S&M, G&A expenses	(47)	(620)	(1,026)
Other operating income	129	11,599	11,933
Operating profit/loss (–)	302	(1,537)	(801)
Net financial results	1,026	1,921	2,676
Taxes	(557)	(532)	(483)
Net profit/loss (–) from discontinued operations, net of tax	771	(148)	1,392

(thousands of €, if not stated otherwise)	**Six months ended June 30, 2026**	Six months ended June 30, 2025	Year ended December 31, 2025
Balance sheet			
Cash and cash equivalents	135,952	71,669	87,868
Financial investments	2,103,597	3,019,835	2,910,180
R&D incentives receivables	125,713	147,672	157,870
Assets	3,351,188	3,818,224	3,406,518
Shareholders' equity	3,263,630	2,643,819	3,235,868
Deferred income	33	954,066	32
Other liabilities	87,525	220,339	170,618
Cash flow			
Operational cash burn	(63,617)	(91,529)	(189,141)
Cash flow used in operating activities	(116,841)	(147,388)	(257,456)
Cash flow generated from investing activities	162,914	159,452	288,814
Cash flow used in financing activities	(4,448)	(1,611)	(3,273)
Increase in cash and cash equivalents	41,625	10,453	28,085
Effect of currency exchange rate fluctuation on cash and cash equivalents	6,459	(3,023)	(4,456)
Cash and cash equivalents at the end of the period	135,952	71,669	87,868
Financial investments at the end of the period	2,103,597	3,019,835	2,910,180
Total financial investments and cash and cash equivalents at the end of the period	2,239,549	3,091,504	2,998,048
Financial ratios			
Number of shares issued at the end of the period	65,897,071	65,897,071	65,897,071
Basic and diluted earnings/loss (–) per share	0.25	(3.93)	4.87
Share price at the end of the period (in €)	26.22	23.76	28.00
Total group employees at the end of the period (number)	196	558	452

First-Half 2026 Financial Results

- Total operating loss from continuing operations for the six months ended June 30, 2026, was €107.2 million, compared to an operating loss of €215.7 million for the six months ended June 30, 2025. This operating loss in 2025 was negatively impacted by the executed strategic reorganization for a total of €131.6 million. This was reflected in severance costs of €47.5 million, costs for early termination of collaborations of €45.7 million, impairment on fixed assets related to small molecules activities of €12.0 million, professional services costs of €16.6 million, €8.0 million accelerated non-cash cost recognition for subscription right plans related to good leavers and €1.8 million other expenses.

- Total net revenues for the six months ended June 30, 2026, amounted to €18.6 million, compared to €140.3 million for the six months ended June 30, 2025. The revenue recognition related to the exclusive access rights granted to Gilead for our drug discovery platform amounted to €115.1 million for the first six months of 2025. The deferred income balance allocated to our drug discovery platform was fully released in revenue at the end of 2025. We reported €14.0 million of Jyseleca® supplies revenues to Alfasigma for the first six months of 2026 (compared to €18.5 million for the same period last year). We have recognized royalty income from Gilead for Jyseleca® for €4.5 million in the first six months of 2026 (compared to €5.6 million in the same period last year).

- Cost of sales for the six months ended June 30, 2026, amounted to €13.9 million, compared to €18.4 million in the same period last year, and related to the supply of Jyseleca® to Alfasigma under the transition agreement.

- R&D expenses in the first six months of 2026 amounted to €56.5 million, compared to €278.0 million for the first six months of 2025. This decrease was primarily explained by a decrease in subcontracting cost from €141.0 million in the first half-year of 2025 to €25.2 million in the first half-year of 2026 due to decreased costs for cell therapy and small molecule programs in oncology, and costs for early termination of collaborations recorded in the first half of 2025. Personnel costs decreased from €82.3 million in the first half of 2025 to €24.9 million for the same period this year due to severance costs in the first six months in 2025. Depreciation and impairment expenses decreased from €32.2 million in the first six months of 2025 to €1.6 million in the first six months of 2026 due to impairments on fixed assets related to small molecules activities recorded in the first half of 2025 and the lack of the amortizations on intangibles from the CellPoint acquisition in the first half of 2026 due to the impairment on the cell therapy activities booked end of 2025.

- S&M expenses amounted to €5.8 million in the first six months of 2026, compared to €1.6 million in the first six months of 2025. The increase related to the reversal of a bad debt provision on Alfasigma receivables in the first half of 2025 and higher legal and professional fees in the first half 2026 due to transaction cost related to the Ouro deal, partly offset by a decrease in personnel expenses in the first half of 2026.

- G&A expenses amounted to €52.2 million in the first six months of 2026, compared to €72.9 million in the first six months of 2025. The decrease in legal and professional fees mainly related to professional services costs recognized in the first six months of 2025, while the decrease in personnel expenses of €10.2 million (from €37.1 million in the first six months of 2025 to €26.9 million in the same period this year) was due to higher severance costs recorded in the first half-year of 2025.

- Other operating income amounted to €2.6 million in the first six months of 2026, compared to €14.9 million for the same period last year, mainly driven by a reduction of R&D incentives income.

Net financial income in the first six months of 2026 amounted to €123.2 million (as compared to net financial loss of €45.0 million in the same period last year) and consisted mainly of €25.0 million interest income (as compared to €21.8 million interest income in the same period last year). Net financial income in the first six months of 2026 also included €38.8 million of unrealized currency exchange gain on our cash and cash equivalents and current financial investments at amortized cost in U.S. dollar (as compared to €37.9 million unrealized currency exchange loss on cash and cash equivalents and current financial investments in the first six months of 2025), as a result of the fluctuation of the U.S. dollar, and €52.4 million positive changes in fair value of current financial investments (€49.9 million negative changes in the same period last year).

We had €0.1 million of tax expense for the first six months of 2026 (as compared to €1.8 million tax income for the same period last year).

Net profit from continuing operations for the first six months of 2026 was €15.8 million, compared to a net loss from continuing operations of €259.0 million for the same period last year.

Net profit from discontinued operations related to Jyseleca® amounted to €0.8 million for the first six months of 2026, compared to a net loss amounting to €0.1 million for the first six months of 2025.

We reported a net profit for the six months ended June 30, 2026, of €16.6 million, as compared to a net loss of €259.1 million for the six months ended June 30, 2025.

Cash, Cash Equivalents and Financial Investments

Cash and cash equivalents and financial investments totaled €2,239.5 million as of June 30, 2026 (€2,998.0 million as of December 31, 2025).

On June 30, 2026, our cash and cash equivalents and current financial investments included $1,962.2 million held in U.S. dollars ($2,159.0 million on December 31, 2025) which could generate foreign exchange gains or losses in our financial results in accordance with the fluctuation of the EUR/U.S. dollar exchange rate as our functional currency is EUR (translated at a rate of 1.1394 €/$ at June 30, 2026).

A net decrease of €758.5 million in cash and cash equivalents and financial investments was recorded during the first six months of 2026, compared to a net decrease of €226.3 million during the first six months of 2025.

This net decrease was composed of (i) €63.6 million of operational cash burn, which includes cash in of €78.4 million related to the return on financial investments, (ii) €38.5 million of positive exchange rate differences, changes in fair value of current financial investments and variation in accrued interest income, (iii) €1.1 million acquisition of equity investments, (iv) €733.5 million of net cash out related to the acquisition of Ouro Medicines, (v) €2.9 million purchase of own shares, partly offset by (vi) €4.1 million of net cash in related to the sale of subsidiaries.

The operational cash burn (or operational cash flow if this liquidity measure is positive) is a financial measure that is not calculated in accordance with IFRS. Operational cash burn/cash flow is defined as the increase or decrease in our cash and cash equivalents (excluding the effect of exchange rate differences on cash and cash equivalents), minus:

1. the net proceeds, if any, from share capital and share premium increases included in the net cash flows generated from/used in (–) financing activities.

2. the net proceeds or cash used, if any, in acquisitions or disposals of businesses; the acquisition of equity investments held at fair value; the movement in restricted cash and movement in financial investments, if any, the loans and advances given to third parties, if any, included in the net cash flows generated from/used in (–) investing activities.

3. the cash used for other liabilities related to the acquisition or disposal of businesses, if any, included in the net cash flows generated from/used in (–) operating activities.

4. the cash used for the purchase of own shares.

This alternative liquidity measure is in our view an important metric for a biotech company in the development stage.

The following table provides a reconciliation of the operational cash burn:

(thousands of €)	Six months ended June 30 2026	2025
Increase in cash and cash equivalents (excluding effect of exchange differences)	41,625	10,453
Less:		
Convertible loan issued to third party	62	20,000
Net sale of financial investments	(838,614)	(114,041)
Acquisition of equity investments held at fair value through other comprehensive income	1,031	–
Cash in from the disposal of subsidiaries, net of cash disposed of	(4,112)	(9,733)
Cash used for other liabilities related to the acquisition of subsidiaries	–	1,792
Purchase of own shares	2,870	–
Cash out from acquisition of subsidiaries, net of cash acquired	733,521	–
Total operational cash burn	**(63,617)**	**(91,529)**

The Lakefront Biotherapeutics Share

Lakefront Biotherapeutics NV (ticker: LKFT) has been listed on Euronext Amsterdam and Brussels since May 6, 2005 and on the Nasdaq Global Select Market since May 14, 2015.

Performance of the Lakefront Biotherapeutics share on Euronext and Nasdaq



Related Party Transactions

We refer to the statements included under the heading "**Related party transactions**" in the "Notes to the unaudited condensed consolidated interim financial statements for the first six months of 2026" part of this report.

Risk Factors

We refer to the **description of risk factors in our 2025 annual report**, pp. 135 – 151, as supplemented by the description of risk factors in our annual report on Form 20-F filed with the U.S. Securities and Exchange Commission ("SEC"), pp. 4 – 74. In summary of the foregoing, the principal risks and uncertainties faced by us relate to and include, but are not limited to: product development and regulatory approval, commercialization, our financial position and need for additional capital, our reliance on third parties, our intellectual property, our business development strategy, our competitive position, our organization, structure and operation, and market risks relating to our shares and ADSs.

We also refer to the **description of the group's financial risk management given in the 2025 annual report**, pp. 219 – 222, which remains valid and unaltered.

Statement by the Board of Directors

The Board of Directors of Lakefront Biotherapeutics NV declares that, as far as it is aware, the financial statements in this half-year 2026 report are prepared according to the applicable standards for financial statements, and give a true and fair view of the equity, financial position and the results of Lakefront Biotherapeutics NV and its consolidated companies.

The Board of Directors of Lakefront Biotherapeutics NV further declares that this half-year 2026 report gives a true and fair view on the important developments and significant transactions with related parties in the first six months of the current financial year and their impact on the interim financial statements, as well as on the most important risks and uncertainties pertaining to the remainder of the current financial year.

Mechelen, August 5, 2026.

On behalf of the Board of Directors,

Gino Santini
Chair of the Board of Directors

Neil Johnston
Chair of the Audit Committee and member of the Board of Directors

Financial Statements

Financial Statements

Unaudited Condensed Consolidated Interim Financial Statements for the First Six Months of 2026

Consolidated Statement of Income and Comprehensive Income/Loss (–) (unaudited)

Consolidated income statement

	Six months ended June 30	
(thousands of €, except per share data)	**2026**	2025
Supply revenues	14,049	18,486
Collaboration revenues	4,542	121,779
Total net revenues	**18,591**	**140,265**
Cost of sales	(13,944)	(18,435)
Research and development expenses	(56,486)	(278,027)
Sales and marketing expenses	(5,826)	(1,556)
General and administrative expenses	(52,184)	(72,914)
Other operating income	2,635	14,932
Operating loss	**(107,214)**	**(215,735)**
Fair value adjustments and net currency exchange differences	97,119	(66,228)
Other financial income	26,479	22,536
Other financial expenses	(414)	(1,364)
Profit/loss (–) before tax	**15,970**	**(260,791)**
Income taxes	(140)	1,788
Net profit/loss (–) from continuing operations	**15,830**	**(259,003)**
Net profit/loss (–) from discontinued operations, net of tax	**771**	**(148)**
Net profit/loss (–)	**16,601**	**(259,151)**

(thousands of €, except per share data)	Six months ended June 30 2026	2025
Net profit/loss (–) attributable to:		
Owners of the parent	16,601	(259,151)
Basic and diluted earnings/loss (–) per share	**0.25**	**(3.93)**
Basic and diluted earnings/loss (–) per share from continuing operations	**0.24**	**(3.93)**

The accompanying **notes** form an integral part of these condensed consolidated financial statements.

Consolidated statement of comprehensive income/loss (–)

(thousands of €)	Six months ended June 30 2026	2025
Net profit/loss (–)	**16,601**	**(259,151)**
Items that will not be reclassified subsequently to profit or loss:		
Fair value adjustment financial assets held at fair value through other comprehensive income	469	(6,012)
Items that may be reclassified subsequently to profit or loss:		
Translation differences, arisen from translating foreign activities	9,990	(618)
Other comprehensive income/loss (–), net of income tax	**10,459**	**(6,630)**
Total comprehensive income/loss (–) attributable to:		
Owners of the parent	27,060	(265,781)
Total comprehensive income/loss (–) attributable to owners of the parent arises from:		
Continuing operations	26,289	(265,633)
Discontinued operations	771	(148)
Total comprehensive income/loss (–), net of income tax	**27,060**	**(265,781)**

The accompanying **notes** form an integral part of these condensed consolidated financial statements.

Consolidated Statement of Financial Position (unaudited)

(thousands of €)	June 30 **2026**	December 31 2025
Assets		
Intangible assets	750,659	848
Property, plant and equipment	76,885	80,663
Deferred tax assets	134	195
Non-current R&D incentives receivables	93,112	126,662
Non-current contingent consideration receivable	44,441	47,750
Equity investments	73,857	46,809
Other non-current assets	2,677	2,959
Convertible loan	62	21,175
Non-current assets	**1,041,827**	**327,061**
Inventories	8,544	22,493
Trade and other receivables	23,695	20,706
Current R&D incentives receivables	32,601	31,208
Current financial investments	2,103,597	2,910,180
Cash and cash equivalents	135,952	87,868
Other current assets	3,963	7,002
Current assets from continuing operations	**2,308,352**	**3,079,457**
Assets in disposal group classified as held for sale	**1,009**	**–**
Total current assets	**2,309,361**	**3,079,457**
Total assets	**3,351,188**	**3,406,518**

(thousands of €)	June 30 **2026**	December 31 2025
Equity and liabilities		
Share capital	293,937	293,937
Share premium account	2,736,994	2,736,994
Other reserves	(8,168)	(8,637)
Translation differences	12,987	2,997
Own shares	(6,078)	–
Accumulated result	233,958	210,577
Total equity	**3,263,630**	**3,235,868**
Non-current lease liabilities	4,773	5,186
Other non-current liabilities	12,461	12,601
Non-current liabilities	**17,234**	**17,787**
Current lease liabilities	1,589	1,729
Trade and other liabilities	66,347	104,647
Provisions	1,402	45,499
Current tax payable	953	956
Current deferred income	33	32
Total current liabilities	**70,324**	**152,863**
Total liabilities	**87,558**	**170,650**
Total equity and liabilities	**3,351,188**	**3,406,518**

The accompanying **notes** form an integral part of these condensed consolidated financial statements.

Consolidated Cash Flow Statement (unaudited)

(thousands of €)	Six months ended June 30 2026	2025
Net profit/loss (–) of the period	**16,601**	**(259,151)**
Decrease (–)/increase in provisions	(44,100)	36,868
Adjustment for other non-cash transactions	(84,749)	131,337
Adjustment for items to disclose separately under operating cash flow	(24,186)	(22,743)
Adjustment for items to disclose under investing and financing cash flows	(6,484)	(41,328)
Change in working capital other than deferred income	1,136	112,335
Cash used for other liabilities related to the acquisition of subsidiaries	–	(1,792)
Decrease in deferred income	–	(117,286)
Cash used in operations	**(141,782)**	**(161,760)**
Interest paid	(127)	(304)
Interest received	25,855	14,880
Corporate taxes paid	(787)	(204)
Net cash flow used in operating activities	**(116,841)**	**(147,388)**
Purchase of property, plant and equipment	(152)	(9,250)
Purchase of intangible fixed assets	–	(155)
Proceeds from disposal of property, plant and equipment	2,399	–
Purchase of financial investments	(902,036)	(2,087,499)
Investment income received related to financial investments	52,555	42,338
Sale of financial investments	1,740,650	2,201,540
Proceeds from settlement of hedging instrument	–	22,745
Cash in from the disposal of subsidiaries, net of cash disposed of	4,112	9,733
Convertible loan issued to third party	(62)	(20,000)
Acquisition of equity investments held at fair value through other comprehensive income	(1,031)	–
Cash out from acquisition of subsidiaries, net of cash acquired	(733,521)	–
Net cash flow generated from investing activities	**162,914**	**159,452**
Payment of lease liabilities	(1,578)	(1,611)
Purchase of own shares	(2,870)	–
Net cash flow used in financing activities	**(4,448)**	**(1,611)**
Increase in cash and cash equivalents	**41,625**	**10,453**

(thousands of €)	Six months ended June 30 2026	2025
Cash and cash equivalents at beginning of the period	**87,868**	**64,239**
Increase in cash and cash equivalents	41,625	10,453
Effect of exchange rate differences on cash and cash equivalents	6,459	(3,023)
Cash and cash equivalents at end of the period	**135,952**	**71,669**

The accompanying **notes** form an integral part of these condensed consolidated financial statements.

Consolidated Statement of Changes in Equity (unaudited)

(thousands of €)	Share capital	Share premium account	Own shares	Translation differences	Other reserves	Accumul. result	**Total**
On January 1, 2025	**293,937**	**2,736,994**	**–**	**3,472**	**(3,158)**	**(134,306)**	**2,896,939**
Net loss						(259,151)	(259,151)
Other comprehensive loss				(573)	(6,057)		(6,630)
Total comprehensive loss				**(573)**	**(6,057)**	**(259,151)**	**(265,781)**
Share-based compensation						12,661	12,661
On June 30, 2025	**293,937**	**2,736,994**	**–**	**2,899**	**(9,215)**	**(380,796)**	**2,643,819**
On January 1, 2026	**293,937**	**2,736,994**	**–**	**2,997**	**(8,637)**	**210,577**	**3,235,868**
Net profit						16,601	16,601
Other comprehensive income				9,990	469		10,459
Total comprehensive income				**9,990**	**469**	**16,601**	**27,060**
Purchase of own shares			(6,078)				(6,078)
Share-based compensation						6,780	6,780
On June 30, 2026	**293,937**	**2,736,994**	**(6,078)**	**12,987**	**(8,168)**	**233,958**	**3,263,630**

The accompanying **notes** form an integral part of these condensed consolidated financial statements.

Notes to the Unaudited Condensed Consolidated Interim Financial Statements for the First Six Months of 2026

Basis of Preparation

These condensed consolidated interim financial statements have been prepared in accordance with IAS 34 'Interim Financial Reporting' as adopted by the European Union. The condensed consolidated interim financial statements do not contain all information required for an annual report and should therefore be read in conjunction with our **Annual Report 2025**.

Material Accounting Policies

There were no significant changes in accounting policies applied by us in these condensed consolidated interim financial statements compared to those used in the most recent annual consolidated financial statements of December 31, 2025.

New standards and interpretations applicable for the annual period beginning on January 1, 2026 did not have any material impact on our condensed consolidated interim financial statements.

We have not early adopted any other standard, interpretation, or amendment that has been issued but is not yet effective. We are currently still assessing the impact of these new accounting standards and amendments that are not yet effective, but we expect no standard to have a material impact on our financial statements in the period of initial application except for the effect of IFRS 18 (effective for the period beginning January 1, 2027). We refer to our **Annual Report 2025** for more detailed information.

Summary of Significant Transactions

Acquisition of Ouro Medicines and collaboration with Gilead Sciences, Inc. ("Gilead")

Framework Agreement with Gilead

On March 23, 2026, Gilead announced that it had entered into a definitive agreement to acquire all of the outstanding equity interests of Ouro Medicines Inc. ("Ouro" or "Ouro Medicines") for a total upfront cash consideration of $1.675 billion, subject to customary adjustments, and up to $500 million in contingent milestone payments (the "Acquisition"). In connection with the Acquisition, we have entered into a Framework Agreement with Gilead, which comprises the following components:

i. relief under the Option, License and Collaboration Agreement dated July 14, 2019 between Gilead and us (the "OLCA"), to enable us to deploy at least $500 million of our available cash independently from Gilead and outside the scope of the OLCA and the Ouro transaction, including up to $150 million for share buybacks (the "OLCA Waiver") – for more information on the OLCA please refer to the Annual Report 2025;

ii. a binding term sheet granting us licenses to certain intellectual property rights relating to Ouro's research programs, including Ouro's lead program of gamgertamig for development purposes, and to the BCMAxCD19xCD3 T cell engager program and other preclinical programs for development and commercialization purposes (the "Licensing Term Sheet"); and

iii. a binding term sheet pursuant to which we would acquire substantially all Ouro's operational assets in connection with the Acquisition, including facilities and personnel, such that we would obtain an operating business (the "Asset Acquisition Term Sheet").

The acquisition by Gilead was completed on June 3, 2026 and the Framework Agreement came into effect at the same date, followed by the aquisition by us on June 4, 2026.

Financial details of the Framework Agreement

Under the Framework Agreement, our share of the total consideration for the Acquisition amounts to 50% of the upfront consideration of $1.675 billion and 50% of any contingent milestone payments, which also includes the consideration under the Asset Acquisition Term Sheet.

Under the Licensing Term Sheet, we are required to fund our share of payments owed to Keymed Biosciences Chengdu Co., Ltd ("Keymed") under the head license agreement between Keymed and Ouro (the "Keymed Agreement"), comprising 25% of the milestone payments and 50% of the royalty payments that become due to Keymed with respect to gamgertamig products. Based on Ouro's original transaction with Keymed, Keymed owns the right to develop the program in Greater China and is entitled to total development and commercial milestones of up to $610 million and tiered royalties of 7% – 14% on net sales of gamgertamig.

We will also bear all costs of development prior to registrational studies for gamgertamig pursuant to agreed-upon research plans and budgets, including Ouro's current clinical trials, while costs of registration-enabling clinical development would be shared equally between the parties, with execution leadership divided by indication.

We are eligible for up to $100 million in milestone payments upon Gilead's initiation of the first registrational trials for gamgertamig in certain other indications.

Gilead will be responsible for commercialization, including all related costs, globally outside of Keymed's territories. Upon commercialization, Gilead will pay us tiered royalties between 20 – 23% on net sales of gamgertamig.

In addition, we in-licensed a preclinical portfolio of three additional autoimmune focused programs originally from Ouro, on which Gilead has the option to opt into a 50/50 profit split post clinical proof-of-concept for $75 million per program.

The OLCA Waiver allows us to spend $500 million of cash (and any additional cash generated from that amount) to acquire or develop research programs independently from Gilead and not subject to Gilead's rights under the OLCA. In addition, we can elect to use up to $150 million of that $500 million for potential share repurchases, dividend payments and other distributions of our capital stock, subject to certain limitations.

Acquisition of Ouro Medicines Inc.

On June 4, 2026, through our acquisition of 100% of the shares of Ouro Medicines Inc. renamed as Lakefront Biotherapeutics West LLC, we have acquired substantially all of Ouro Medicines' team including 25 FTEs and operational assets in connection with Gilead's acquisition of Ouro Medicines and will collaborate with Gilead on the development of gamgertamig (an investigational BCMAxCD3 bispecific T-cell engager for the treatment of autoantibodies driven immune-mediated disease).

The main reason for this acquisition is to invest in differentiated science and accelerate the development of therapies that address significant unmet need. Combined with existing expertise in immunology and cell therapy, this approach supports our ambition to shift treatment paradigms from chronic disease management toward the potential for durable immune reset.

The acquisition of Ouro Medicines Inc. (now renamed Lakefront Biotherapeutics West LLC) is further described in the notes to our interim consolidated financial statements.

Conversion of convertible loan to Coultreon Biopharma BV into shares

In April 2025, we participated in Onco3R's start-up capital via a convertible loan facility of €20 million, which would convert during the next equity financing round. Onco3R Therapeutics BV was renamed to Coultreon Biopharma BV ("Coultreon"). This convertible loan facility was presented in the line "Convertible loan" in our **statement of financial position** and was measured at fair value through profit or loss.

In April 2026, Coultreon announced the closing of an oversubscribed $125 million Series A financing round. The financing will support the clinical development of Coultreon's lead immunology program, COL-5671 (formerly O3R-5671), a highly selective SIK3 inhibitor in Phase 1, with potential to demonstrate clinical proof-of-concept in 2027. COL-5671 was initially developed by Lakefront and ownership was fully transferred to Coultreon in April 2025, when Lakefront provided seed financing to the company with a convertible note investment that converted into equity ownership in Coultreon in

connection with Series A financing. As of June 30, 2026, Lakefront holds 29.12% of Coultreon's currently issued and outstanding shares.

Share Repurchase Program

At the Extraordinary Shareholder Meeting held on April 28, 2026 (the "2026 EGM"), it was resolved to authorize the Board of Directors, without prior authorization of the Shareholders' Meeting, in accordance with Belgian law and within the limits provided, to acquire a maximum of ten per cent (10%) of the number of shares existing at the end of the 2026 EGM, for a consideration equivalent to the closing price of Lakefront's share on Euronext Brussels, on the day immediately preceding the acquisition, plus a maximum of fifteen percent (15%) or minus a maximum of fifteen percent (15%). This authorization is valid for five years from the date of the publication in the Annexes to the Belgian State Gazette of the minutes of the 2026 EGM.

On June 9, 2026, we announced the launch of a share repurchase program (the "Program"), under which we may repurchase ordinary shares for an aggregate amount of up to €50 million. Repurchases under the Program may be made no later than December 31, 2026. The Program is entered into via a discretionary mandate with Morgan Stanley & Co International PLC.

As of June 30, 2026, we were holding 241,904 of our own ordinary shares, for a total purchase value of €6,078,112.05 at an average price of €25.13 per share (of which €2,869,971.03 was paid in cash and €3,208,141.02 still to be paid on June 30, 2026). The outstanding amount (unpaid) represents a financial liability that was presented as part of the trade and other liabilities line in our consolidated statement of financial position. The purchase value is disclosed on the line "Own shares" in our consolidated statement of changes in equity.

Critical Accounting Judgements and Key Sources of Estimation Uncertainty

There were no significant changes in our critical accounting judgements and key sources of estimations uncertainty compared to those used in the most recent annual consolidated financial statements of December 31, 2025, except for the following new critical accounting judgements and key sources of estimation uncertainty.

Key sources of estimation

Determination of fair value of convertible loan receivable

As there is no active market for the convertible loan and no reference share value is readily available of Coultreon, which is a very early-stage R&D organization at the moment, we establish the fair value by using other valuation techniques. The fair value has been determined mainly by reference to the initial transaction price and adjusted as necessary for impairment and revaluations with reference to capitalized interests, relevant available information and recent financing rounds.

The convertible loan receivable was converted into equity ownership in Coultreon in connection with Series A financing in April 2026. As a result, the convertible loan receivable was reclassified to an equity instrument held at fair value through other comprehensive income. The fair value of equity instruments is estimated by management based on the cost of investment and adjusted as necessary for impairment and revaluations with reference to relevant available information and recent financing rounds. The inputs are categorized as Level 3 inputs. We refer to our **Annual Report 2025** for more detailed information.

Critical accounting judgements

Equity investment – Coultreon

Our convertible loan receivable in Coultreon was converted into 29.12% of current equity ownership in Coultreon following the successful completion of Coultreon's Series A Financing round. Although after conversion of the convertible loan, we hold 29.12% of currently issued and outstanding shares and corresponding voting rights, we concluded significant influence not to exist as we do not have representation on the Board of Directors, only holding a non-voting observer position, and we do not have substantive rights to participate in financial and operating policy decisions under the current shareholder agreement. Accordingly, the investment is accounted for as an equity instrument measured at fair value through other comprehensive income in accordance with IFRS 9 rather than as an investment in an associate under IAS 28.

Details of the Unaudited Condensed Consolidated Interim Results

Collaboration revenues

The following table summarizes our collaboration revenues for the six months ended June 30, 2026 and 2025:

			Six months ended June 30	
(thousands of €)	Over time	Point in time	**2026**	2025
Recognition of non-refundable upfront payments and license fees			**–**	**116,226**
Gilead collaboration agreement for drug discovery platform	✓		–	115,046
Cartilla Therapeutics GLPG1972		✓	–	1,180
Royalties			**4,542**	**5,553**
Gilead royalties on Jyseleca®		✓	4,542	5,553
Total collaboration revenues			**4,542**	**121,779**

Operating costs and other operating income

Operating costs

Research and development expenditure

The following table summarizes our research and development expenditure for the six months ended June 30, 2026 and 2025:

	Six months ended June 30	
(thousands of €)	**2026**	2025
Personnel costs	(24,856)	(82,282)
Subcontracting	(25,227)	(141,001)
Disposables and lab fees and premises costs	(1,056)	(6,575)
Amortization, depreciation and impairment	(1,597)	(32,232)
Professional fees	(639)	(5,693)
Other operating expenses	(3,111)	(10,244)
Total research and development expenses	**(56,486)**	**(278,027)**

The decrease in research and development expenses was primarily attributable to the strategic reorganization and the wind-down of the cell therapy activities in 2025. As a result, the comparative period included significant non-recurring expenses that were absent or substantially lower in the current period, principally:

- subcontracting costs related wind-down of the cell therapy and small molecule programs, including expenses associated with the early termination of collaboration agreements;
- severance costs included in personnel expenses; and
- impairment, amortization and depreciation charges relating to fixed assets associated with the discontinued small molecule programs and wind down of the cell therapy activities.

The table below summarizes our R&D expenditure for the six months ended June 30, 2026 and 2025, broken down by program.

	Six months ended June 30	
(thousands of €)	**2026**	2025
SIKi program	(85)	(9,054)
TYK2 program on GLPG3667	(11,674)	(16,306)
Cell therapy programs in oncology	(38,754)	(115,978)
Gamgertamig	(1,190)	–
Other discovery programs	(4,783)	(136,689)
Total research and development expenses	**(56,486)**	**(278,027)**

The research and development expenses decreased in the first half of 2026 compared to the same period last year, primarily due to the strategic reorganization and the wind-down of the cell therapy activities in 2025, which resulted in a decrease of expenses for the different existing programs.

Sales and marketing expenses

The following table summarizes our sales and marketing expenses for the six months ended June 30, 2026 and 2025:

	Six months ended June 30	
(thousands of €)	**2026**	2025
Personnel costs	(2,931)	(4,061)
Amortization, depreciation and impairment	(11)	3,755
External outsourcing costs	(2,676)	(520)
Professional fees	–	(93)
Other operating expenses	(208)	(637)
Total sales and marketing expenses	**(5,826)**	**(1,556)**

General and administrative expenses

The following table summarizes our general and administrative expenses for the six months ended June 30, 2026 and 2025:

	Six months ended June 30	
(thousands of €)	**2026**	2025
Personnel costs	(26,941)	(37,126)
Amortization, depreciation and impairment	(1,432)	(4,044)
Legal and professional fees	(10,464)	(20,794)
Other operating expenses	(13,347)	(10,950)
Total general and administrative expenses	**(52,184)**	**(72,914)**

Personnel costs decreased due to severance accruals recorded in the first half of 2025. Legal and professional fees should be considered together with other operating expenses, the total of both decreased due to one-off professional fees linked to the small molecules restructuring recorded in the first half of 2025.

Other operating income

The following table summarizes our other operating income for the six months ended June 30, 2026 and 2025:

	Six months ended June 30	
(thousands of €)	**2026**	2025
Grant income	–	57
R&D incentives income	2,314	11,946
Other	321	2,929
Total other operating income	**2,635**	**14,932**

Lower R&D incentives as a result of the strategic reorganization and wind down of the cell therapy activities explain the decrease in other operating income.

Financial income/expenses

The following table summarizes our financial income/expenses (–) for the six months ended June 30, 2026 and 2025:

	Six months ended June 30	
(thousands of €)	**2026**	2025
Fair value adjustments and net currency exchange differences:		
Net unrealized currency exchange gain/loss (–)	40,563	(38,430)
Net realized currency exchange loss	(204)	(945)
Fair value gain on financial assets held at fair value	4,311	347
Gain from settlement of hedging instrument	–	22,745
Fair value gain/loss (–) on current financial investments	52,449	(49,945)
Total fair value adjustments and net currency exchange differences	**97,119**	**(66,228)**
Other financial income:		
Interest income	25,010	21,791
Discounting effect of non-current R&D incentives receivables	1,284	727
Other finance income	185	18
Total other financial income	**26,479**	**22,536**
Other financial expenses:		
Interest expenses	(127)	(304)
Discounting effect of other non-current liabilities	–	(661)
Other finance charges	(287)	(399)
Total other financial expenses	**(414)**	**(1,364)**
Total net financial result	**123,183**	**(45,056)**

Fair value adjustments and net currency differences increased due to the evolution of the USD exchange rate.

Discontinued operations

The following disclosure illustrates the result from our discontinued operations, related to the transfer of the Jyseleca® business to Alfasigma on January 31, 2024.

1.1 Net cash inflow on disposal of the Jyseleca® business

	Six months ended June 30	Six months ended June 30
(thousands of €)	**2026**	**2025**
Release from escrow account	–	18,323
Contribution for R&D costs paid by us to Alfasigma	–	25,000
Earn-outs paid by Alfasigma	4,205	4,217
Cash in/cash out (-) from the disposal of subsidiaries, net of cash disposed of	**4,205**	**(2,459)**

1.2 Result from discontinued operations

(thousands of €, except per share data)	Six months ended June 30 2026	2025
Research and development expenses	220	(12,516)
Sales and marketing expenses	–	(588)
General and administrative expenses	(47)	(32)
Other operating income	129	11,599
Operating profit/loss (–)	**302**	**(1,537)**
Other financial income	1,026	1,921
Profit before tax	**1,328**	**384**
Income taxes	(557)	(532)
Net profit/loss (–)	**771**	**(148)**
Basic and diluted earnings/loss (–) per share from discontinued operations	**0.01**	**0.00**
Weighted average number of shares – Basic (in thousands of shares)	65,885	65,897
Weighted average number of shares – Diluted (in thousands of shares)	65,954	65,897

For the six months ending June 30, 2025, the R&D expenses related to the settlement of disputed expenses with Alfasigma.

Other operating income for the first six months of 2025, included a fair value adjustment of the contingent consideration receivable from Alfasigma as a consequence of an adjusted sales forecast.

Other financial income contains discounting components on the contingent consideration receivables.

1.3 Cash flow from discontinued operations

(thousands of €)	Six months ended June 30 2026	2025
Net cash flow used in operating activities	(384)	(555)
Net cash flow generated from/used (–) in investing activities	4,205	(2,459)
Net cash flow generated from/used in (–) discontinued operations	**3,821**	**(3,014)**

Net Asset acquisition – Ouro Medicines

On June 4, 2026, Gilead acquired all the outstanding equity of Ouro Medicines for $1,675 million and up to $500 million in contingent milestone payments. We and Gilead will equally split the upfront payment, subject to customary adjustments, and contingent milestone payments of up to $500 million.

On June 4, 2026, through our acquisition of 100% of the shares of Ouro Medicines, we have acquired substantially all of Ouro Medicines' team including 25 FTEs and operational assets and assumed transferred liabilities in connection with Gilead's acquisition of Ouro Medicines and we will collaborate with Gilead on the development of gamgertamig. Gamgertamig is an investigational BCMAxCD3 bispecific T-cell engager for the treatment of autoantibodies driven immune-mediated disease. Gamgertamig is in-licensed from Keymed Biosciences, which owns the rights to develop the program in Greater China.

By applying the optional concentration test as described under IFRS 3 Business Combinations, 98.0% of the fair value of the gross assets acquired is concentrated in the OM336 compound. As substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset, the acquisition of Ouro Medicines does not represent the acquisition of a business but rather the acquisition of net assets.

The cost of the acquisition (the upfront payment and $16.3 million of direct acquisition costs) is to be allocated to the individual identifiable assets and liabilities based on their relative fair values at the date of acquisition. We applied an approach whereby any identifiable asset or liability initially measured at an amount other than costs, is initially measured at the amount specified in the IFRS Accounting Standard. We deducted from the cost of the acquisition the amounts allocated to the assets and liabilities initially measured at an amount other than cost, and then allocated the residual transaction price to the remaining identifiable assets and liabilities based on their relative fair values at the date of acquisition.

This approach resulted in the following net assets recognized at acquisition date (based on the initial recognition exemption in IAS 12 Income Taxes, no deferred tax liabilities were recognized):

	June 4, 2026
	OURO Medicines
(thousands of €)	At cost
Intangible assets	734,165
Property, plant and equipment	510
Other non-current assets	41
Trade and other receivables	3,020
Cash and cash equivalents	19,132
Other current assets	48
Non-current lease liabilities	(190)
Current lease liabilities	(174)
Trade and other liabilities	(3,565)
Net assets acquired	**752,986**
Net cash outflow arising on acquisition	
Consideration paid in cash	743,255
Transaction costs paid in cash	9,398
Less: cash and cash equivalents balances acquired	(19,132)
Cash out from the acquisition of subsidiaries, net of cash acquired	**733,521**

In the absence of any guidance in IFRS Accounting Standards regarding the accounting for variable payments for the purchase of net assets which is not part of a business combination, we developed an accounting policy whereby the variable consideration (the "Contingent Consideration") is only recognized as a liability when the condition that triggers the obligation is met. Therefore, each of the contingent milestone payments of up to $250 million (50% of $500 million that shall be paid by us, other 50% by Gilead) will be recognized when the milestone events have been reached. As these milestone events all relate to the further development of OM336, these milestones when recognized, will be added to the cost of the OM 336 compound being recognized.

The Contingent Consideration totals up to a maximum amount of $500 million (50% to be paid from our side) consisting of clinical development milestones up to a maximum amount of $200 million (50% to be paid from our side) and regulatory milestones up to a maximum amount of $300 million (50% to be paid from our side).

Cash position

Cash and cash equivalents and financial investments totaled €2,239.5 million on June 30, 2026 (€2,998.0 million on December 31, 2025).

Cash and cash equivalents and financial investments comprised cash at banks, term deposits, and money market funds. Our cash management strategy monitors and optimizes our liquidity position. Our cash management strategy allows short-term deposits with an original maturity exceeding three months while monitoring all liquidity aspects.

All cash and cash equivalents are available upon maximum three months' notice period and without significant penalty. Cash at banks were mainly composed of current accounts. Our credit risk is mitigated by selecting a panel of highly rated financial institutions for our deposits.

Current financial investments comprised €1,058.8 million of term deposits which all had an original maturity longer than three months and which are not available on demand within three months. Our current financial investments also comprised of money market funds. Our money market funds portfolio consists of AAA short-term money market funds with a diversified and highly rated underlying portfolio managed by established fund management companies with a proven track record.

	June 30	December 31
(thousands of €)	**2026**	2025
Money market funds	1,044,811	1,472,031
Term deposits	1,058,786	1,438,149
Total current financial investments	**2,103,597**	**2,910,180**
Cash at banks	135,952	87,868
Total cash and cash equivalents	**135,952**	**87,868**

On June 30, 2026, our cash and cash equivalents and current financial investments included $1,962.2 million held in U.S. dollars ($2,159.0 million on December 31, 2025) which could generate foreign exchange gains or losses in our financial results in accordance with the fluctuation of the EUR/U.S. dollar exchange rate as our functional currency is EUR. The foreign exchange loss (–)/gain in case of a 10% change in the EUR/U.S. dollar exchange rate amounts to €172.2 million.

Note to the cash flow statement

(thousands of €)	June 30 2026	2025
Adjustment for other non-cash transactions		
Amortization, depreciation and impairment on intangible assets and property, plant and equipment	3,040	36,515
Share-based compensation expenses	6,780	12,661
Decrease in retirement benefit obligations	–	(1)
Unrealized exchange losses/gains (–) and non-cash other financial result	(43,139)	37,707
Discounting effect of other non-current liabilities	–	661
Discounting effect of contingent consideration receivable	(1,026)	(1,921)
Net change in fair value of current financial investments	(45,964)	67,439
Fair value adjustment financial assets held at fair value through profit or loss	(4,311)	(347)
Fair value adjustment contingent consideration receivable	(129)	(11,579)
Impairment loss reversal on trade receivables	–	(9,643)
Other non-cash expenses	–	(155)
Total adjustment for non-cash transactions	**(84,749)**	**131,337**
Adjustment for items to disclose separately under operating cash flow		
Interest expense	127	304
Interest income	(25,010)	(21,791)
Income taxes	697	(1,256)
Total adjustment for items to disclose separately under operating cash flow	**(24,186)**	**(22,743)**
Adjustment for items to disclose under investing and financing cash flows		
Gain on sale of subsidiaries	–	(1,085)
Proceeds from settlement of hedging instrument	–	(22,745)
Investment income on financial investments	(6,484)	(17,498)
Total adjustment for items to disclose separately under investing and financing cash flow	**(6,484)**	**(41,328)**
Change in working capital other than deferred income		
Decrease in inventories	13,948	17,553
Decrease in receivables	36,236	44,842
Increase/decrease (–) in liabilities	(49,048)	49,940
Total change in working capital other than deferred income	**1,136**	**112,335**

Provisions

(thousands of €)	Provisions Restructuring small molecules programs	Restructuring cell therapy activities	**Total provisions**
On January 1, 2026	**29,175**	**16,324**	**45,499**
Unused amount reversed	(529)	(7,227)	**(7,756)**
Amounts settled	(28,646)	(7,240)	**(35,886)**
Other movements	–	(455)	**(455)**
On June 30, 2026	**–**	**1,402**	**1,402**

The decrease in the provisions primarily reflected cash payments relating to early termination of collaboration agreements as a result of the discontinuation of the small molecules activities and as a result of the wind-down of the cell therapy activities. In addition, €7.2 million of the provision was reversed following the completion of negotiations with suppliers and the reassessment of expected costs, which resulted in lower settlement amounts than originally estimated. No significant new restructuring provisions were recognized during the period. The remaining provision is expected to be substantially utilized during the second half of 2026.

Financial risk management

The following table summarizes the categories of financial assets and liabilities held at fair value:

(thousands of €)	Fair value hierarchy	June 30 **2026**	December 31 2025
Financial assets held at fair value through other comprehensive income			
Equity investments	Level 3	73,857	46,809
Financial assets held at fair value through profit or loss			
Contingent consideration receivable	Level 3	52,095	54,705
Financial investments	Level 1	1,044,811	1,472,031
Convertible loan	Level 3	62	21,175

The increase of the fair value of the equity investments is due to the conversion of the loan to Coultreon into equity and to an exchange gain of €1.5 million; the latter is reflected in the other reserves (other comprehensive income) in the consolidated equity. The valuation of all our equity investments is based on Level 3 assumptions as it includes investments in non-quoted companies. These investments are valued initially at fair value through the established purchase price between a willing buyer and seller. Subsequent valuation is based on internal and external evidence such as information from recent financing rounds, scientific updates and other valuation techniques.

The contingent consideration receivable relates to fair value of the future earn-outs to be obtained from Alfasigma for the sale of Jyseleca®. €7.8 million is presented on the line “Trade and other receivables” and €44.4 million is presented on the line “non-current contingent consideration receivable”. The total potential amount consists of sales-based milestone payments totaling €120 million and mid-single to mid-double-digit royalties on European sales. The valuation is based on Level 3 assumptions based on our best estimate of the expected earn-outs and sales milestones in the future, considering probability adjusted sales forecasts of Jyseleca® discounted using an appropriate discount rate. The fair value is reviewed at each reporting date and any changes are reflected in our consolidated income statement, in the line ‘Net profit/loss (–) from discontinued operations, net of tax’. A change in expected sales by +15% would result in an increase of €14.3 million in the total contingent consideration receivable on June 30, 2026. A change in expected sales by –15% would result in a decrease of €13.9 million in the total contingent consideration receivable on June 30, 2026.

We refer to **critical accounting judgements and key sources of estimation uncertainty** for details about the fair value of the convertible loan.

Off-balance Sheet Arrangements

Contractual obligations and commitments

We have certain purchase commitments principally with CRO subcontractors and certain collaboration partners.

On June 30, 2026, we had outstanding obligations for purchase commitments, which become due as follows:

(thousands of €)	Total	Less than 1 year	1 – 3 years	3 – 5 years	More than 5 years
Purchase commitments	**81,952**	**60,995**	**13,810**	**2,539**	**4,608**

Our purchase commitments at the end of June 2026 included €55.4 million related to projects in development phase, €1.1 million for projects in discovery research phase, €24.5 million for shared services, and €1.0 million for supply chain, commercial and medical affairs.

We refer to our **Annual Report 2025** for additional information on our contingent contractual obligations.

Related Party Transactions

Key management personnel

On March 6, 2026, the members of the Executive Committee were offered new subscription rights under the Subscription Right Plan 2026, which have all been accepted in full. The subscription rights have an exercise term of eight years as of the date of the notarial deed enacting the acceptance of the subscription rights. The exercise price of the subscription rights is €28.82 (the closing price of the Lakefront share on Euronext Brussels and Amsterdam on the date preceding the offer). Each subscription right gives the right to subscribe for one new Lakefront share. The subscription rights are subject to a 3-year cliff vesting schedule and can in principle not be exercised prior to March 6, 2029.

On March 6, 2026, the members of the Executive Committee were offered new restricted stock units ("RSUs") under the Lakefront 2026 Restricted Stock Units/Long-Term Incentive Plan ("2026 RSU LTIP Plan"). The RSUs were offered for no consideration. Each RSU represents the right to receive, at Lakefront's discretion, one Lakefront share or a payment in cash of an amount equivalent to the volume-weighted average price of the Lakefront share on Euronext Brussels over the 30-calendar day period preceding the relevant vesting date. The RSUs granted under the 2026 RSU LTIP Plan are subject to a 4-year phased vesting schedule, whereby 25% of the RSUs granted will vest on each anniversary date of the date of the grant.

On March 6, 2026, the members of the Executive Committee were offered new performance stock units ("PSUs") under the Lakefront 2026 Performance Stock Units/Long-Term Incentive Plan ("2026 PSU LTIP Plan"). The PSUs were offered for no consideration, but the vesting of the PSUs is subject to meeting certain performance criteria as determined in the 2026 PSU LTIP Plan. Each PSU represents the right to receive, at Lakefront's discretion, one Lakefront share or a payment in cash of an amount equivalent to the volume-weighted average price of the Lakefront share on Euronext Brussels over the 30-calendar day period preceding the relevant vesting date. The PSUs granted under the 2026 PSU LTIP Plan are subject to a 3-year cliff vesting schedule in a range from 0% to 150% and can in principle not vest prior to March 6, 2029.

On April 28, 2026, we held our Annual Shareholders' Meeting ("AGM"). The AGM approved the appointment of Mr. Henry Gosebruch as Executive Director for an additional period of four years, the appointment of Dr. Jane Griffiths as independent non-executive director for an additional period of four years, the appointment of Ms. Dawn Svoronos as independent non-executive director for an additional period of four years, the appointment of Dr. Neil Johnston as independent non-executive director for an additional period of two years, the appointment of Mr. Devang Bhuva as non-executive director for an additional period of three years, the appointment of Dr. Paulo Fontoura as independent non-

executive director for an additional period of three years, the appointment of Mr. Gino Santini as independent non-executive director for an additional period of four years. Mr. Gino Santini was also appointed as the new Chair of the Board of Directors.

The table below sets forth the number of subscription rights offered and accepted under Subscription Right Plan 2026, the number of RSUs and PSUs offered to each member of the Executive Committee during the first six months of 2026:

Name	Title	Number of Offered and Accepted Subscription Rights 2026	Number of Offered and Accepted RSUs 2026	Number of Offered and Accepted PSUs 2026
Henry Gosebruch	CEO	353,700	70,700	70,700
Aaron Cox	Chief Financial Officer	124,400	24,900	24,900
Fred Blakeslee	General Counsel	108,800	21,800	21,800

During the first six months of 2026, other than as disclosed in the paragraph above there were no changes to related party transactions disclosed in the 2025 annual report that potentially had a material impact on our financials of the first six months of 2026.

Events after the End of the Reporting Period

There were no adjusting events nor material non-adjusting events to be reported.

Approval of Interim Financial Statements

The interim financial statements were approved by the Board of Directors on August 5, 2026.

Report of the Statutory Auditor

Statutory Auditor's Report to the Board of Directors of Lakefront Biotherapeutics NV on the Review of Consolidated Interim Financial Information for the Six-Month Period Ended 30 June 2026

Introduction

We have reviewed the accompanying consolidated statement of financial position of Lakefront Biotherapeutics NV as of 30 June 2026 and the related consolidated statements of income and comprehensive income/loss (-), cash flows and changes in equity for the six-month period then ended, as well as the explanatory notes. The Board of Directors is responsible for the preparation and presentation of this consolidated interim financial information in accordance with IAS 34 "Interim Financial Reporting", as adopted by the European Union. Our responsibility is to express a conclusion on this consolidated interim financial information based on our review.

Scope of review

We conducted our review in accordance with International Standard on Review Engagements 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity". A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying consolidated interim financial information is not prepared, in all material respects, in accordance with IAS 34 "Interim Financial Reporting", as adopted by the European Union.

Zaventem, August 10, 2026

BDO Bedrijfsrevisoren BV
Statutory auditor
Represented by Ellen Lombaerts*
Auditor

*Acting for a company

Other Information

Forward-Looking Statements

This report contains forward-looking statements, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “seek,” “upcoming,” “future,” “estimate,” “may,” “will,” “could,” “would,” “potential,” “forward,” “goal,” “next,” “continue,” “should,” “encouraging,” “aim,” “progress,” “remain,” “explore,” “further” as well as similar expressions.

These statements include, but are not limited to, statements regarding our business development strategy, including the collaboration agreement between Gilead Sciences (Gilead) and us and the expected benefits of such collaboration, including the expected benefits from our collaboration with respect to Ouro Medicines (Ouro or Ouro Medicines); statements regarding our corporate transformation, including the changes to our board of directors and management; statements regarding our business and financial condition, including our cash position, the rate and timing of our cash burn, and the proposed uses and allocations of our capital resources; statements regarding the wind down of our cell therapy activities, including regarding the timing and completion thereof; statements regarding the potential attributes and benefits of gamgertamig and our other current and future product candidates, our ability to advance such product candidates into, and successfully complete, clinical trials, and our commercialization efforts for such product candidates and our future approved products, if any. We caution the reader that forward-looking statements are based on our management’s current expectations and beliefs and are not guarantees of future performance. Forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause actual events, financial condition and liquidity, performance or achievements, or the industry in which we operate, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. In addition, even if our results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods.

Such risks include, but are not limited to, the risk that we are not able to realize the benefits of our collaboration with Gilead, including with respect to Ouro; the risk that our financial estimates may be incorrect (including because one or more of its assumptions underlying our revenue or expense expectations may not be realized); the risk that we will not be able to execute on our currently contemplated business plan or strategy and/or will revise our business plan or strategy; risks related to our ability to successfully identify, pursue and consummate new transformational business development transactions, including our ability to identify product candidates that will have commercial success and/or be profitable; the risk that the commercial potential of gamgertamig or our other current and product candidates proves to be inaccurate; the impact of this report on our business relationships, employee retention and hiring, and stock price; the inherent risks and uncertainties associated with competitive developments, clinical trials, recruitment of patients, product development activities and regulatory approval requirements; risks related to our reliance on collaborations with third parties (including, but not limited to, our collaboration partner Gilead); risks associated with our ability to advance product candidates into, and successfully complete, clinical trials, including the inherent uncertainties associated with competitive developments, clinical trial and product development activities, and regulatory approval requirements (including the possibility of unfavorable new clinical data and further analyses of existing clinical data, the risks related to clinical failure at any stage of clinical development); and the risk that our estimates regarding the commercial potential of our product candidates (if approved) or expectations regarding the costs and revenues associated with the commercialization rights may be inaccurate.

A further list and description of these risks, uncertainties and other risks can be found in our filings and reports with the Securities and Exchange Commission (SEC), including in our most recent annual report on Form 20-F filed with the SEC and our subsequent filings and reports filed with the SEC. Given these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition, even if the result of our operations, financial condition and liquidity, or the industry in which we operate, are consistent with such forward-looking statements, they may not be predictive of results, performance or achievements in future periods. These forward-looking statements speak only as of the date of publication of this report. We expressly disclaim any obligation to update any such forward-looking statements in this report to reflect any change in our expectations or any change in events, conditions or circumstances, unless specifically required by law or regulation.

Lakefront Biotherapeutics NV was formerly known as Galapagos NV. Throughout this report, we refer to the company as “Lakefront Biotherapeutics,” “LKFT,” “Lakefront” or “Lakefront Bio.”

Glossary

ADS

American Depositary Share; one ADS is equivalent to one ordinary share

AIHA

Autoimmune hemolytic anemia, a rare autoimmune disease in which the immune system destroys red blood cells

BCMA

B cell maturation antigen, a protein target involved in immune disease biology

BCMAxCD3

Bispecific construct targeting BCMA and CD3 to engage T-cells

CAD

Cold agglutinin disease, a rare autoimmune hemolytic anemia

Cash position

Financial investments and cash and cash equivalents available to the company

Fast Track Designation

FDA designation intended to facilitate development and expedite review of therapies for serious conditions

FDA

U.S. Food and Drug Administration

GALACELA

Phase 2 study with GLPG3667 in patients with systemic lupus erythematosus

GALARISSO

Phase 2 study with GLPG3667 in patients with dermatomyositis

Gamgertamig

Investigational BCMAxCD3 T-cell engager being developed for autoimmune diseases

GLPG3667

TYK2 inhibitor evaluated in dermatomyositis and systemic lupus erythematosus

ITP

Immune thrombocytopenia, an autoimmune disease characterized by low platelet counts

LCA

License and Collaboration Agreement governing development and commercialization rights

OLCA

Option, License and Collaboration Agreement

Orphan Drug Designation

Regulatory designation granted to therapies intended for rare diseases

Pemphigus vulgaris (PV)

Rare autoimmune blistering disease affecting skin and mucous membranes

Phase 1b

Clinical development stage evaluating safety and early activity in patients

Phase 2

Clinical development stage evaluating efficacy, safety and dose selection

Share repurchase program

Program under which a company buys back its own shares

Sjogren's disease

Chronic autoimmune disease affecting moisture-producing glands

Systemic lupus erythematosus (SLE)

Autoimmune disease affecting multiple organs and tissues

T-cell engager

Engineered therapy designed to redirect T cells toward target cells

TYK2

Tyrosine kinase 2, an intracellular signaling protein involved in immune responses

Financial Calendar

November 12, 2026

Third quarter 2026 results

Other Information

Concept, design and online programming

nexxar GmbH, Vienna – Online annual reports and online sustainability reports (**www.nexxar.com**)

Photography

Saskia Vanderstichele
Private photographs

Copy deadline: August 10, 2026

This report is also available in Dutch and available for download at **www.lakefrontbio.com**

Contact

Sherri Spear

Senior Vice President, Investor Relations & Corp Communications
Email: **sherri.spear@lakefrontbio.com**

Liesbeth Verstraeten

Director, Reporting & Sustainability Lead
Email: **liesbeth.verstraeten@lakefrontbio.com**

Listings

Euronext Amsterdam and Brussels: LKFT Nasdaq: LKFT

Lakefront Biotherapeutics NV
Schaliënhoevedreef 20 T
2800 Mechelen
Belgium

lakefrontbio.com